Abstract 221P
Background
The gold standard treatment for the non-muscle invasive bladder cancer (NMIBC) is Bacillus Calmette-Guerin (BCG). the instillation of BCG induces an inflammatory response followed by cytokines upregulation and downregulation with a clinical outcome. In this we are targeting the IL1-alpha and TNF-alpha genes and study their genetic polymorphism to elucidate their role in BCG response and tumor recurrence in NMIBC patients.
Methods
The blood samples collected from histopathologically confirmed 224 NMIBC patients from August 2020 to December 2022. The 124 patients were grouped as BCG nonresponsive (BCG-NR) and 100 patients were grouped under BCG-responsive (BCG-R). The classification of group based on the BCG response followed by SWOG protocol. Recurrence/progression of tumor after 6 months consider for the BCG-NR followed by cystoscopy. In contrast patients with no sign of recurrence and progression after 12 months of BCG therapy consider as BCG-R. The DNA was isolated for the genotypic analysis of IL1A -889 C/T-(rs1800587) and TNFA-1031 T/C (rs1799964), in both groups using Taq-Man Probe-based real-time polymerase chain reactions.
Results
In this study, IL1A -889 C, and TNFA, 1031's C allele frequency, were significantly higher in BCG-NR (P <.05). The IL-1 alpha-889 C/T (CC/CT+TT) and TNFA -1031 T/C (TT/TC+CC) genotype expression were shown to be significantly associated with BCG-NR and tumour recurrence (CC/CT+TT; P=.025, TT/TC+CC; P =0.045) as compared to BCG-R in NMIBC.
Conclusions
The genetic polymorphism of the cytokines IL1A -889 C/T (rs1800587) and TNFA-1031 (rs1799964) T/C is significantly susceptible to the recurrence of tumor, BCG response and lead the way for early therapeutic response in NMIBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract